Μ-opioid

From WikiMD's Wellness Encyclopedia

Μ-opioid receptor (MOR) is a type of opioid receptor with a high affinity for morphine, representing a class of receptors critically involved in the modulation of pain. The μ-opioid receptors are distributed throughout the central nervous system (CNS) and the gastrointestinal tract. Activation of these receptors by endogenous endorphins or exogenous opioids such as morphine can lead to analgesic effects, as well as other physiological responses including changes in mood, respiratory depression, and decreased gastrointestinal motility.

Structure[edit | edit source]

The μ-opioid receptor is a G protein-coupled receptor (GPCR) that, upon activation, inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium conductance. This leads to a decrease in neuronal excitability and neurotransmitter release. The gene encoding the μ-opioid receptor is OPRM1.

Function[edit | edit source]

The primary function of the μ-opioid receptor is the modulation of pain. Activation of MOR can produce profound analgesia, making it a primary target for analgesic drugs. Beyond pain control, MOR activation also affects reward and addictive behaviors, as many opioids have a high potential for dependence and abuse.

Pharmacology[edit | edit source]

Drugs that target the μ-opioid receptor can be classified into three main categories: agonists, antagonists, and partial agonists. Agonists like morphine activate the receptor, leading to its analgesic and other pharmacological effects. Antagonists such as naloxone block the receptor, reversing the effects of opioids and are used in the treatment of opioid overdose. Partial agonists, like buprenorphine, activate the receptor but produce a lesser response compared to full agonists.

Clinical Significance[edit | edit source]

The clinical significance of the μ-opioid receptor is vast, given its role in pain management and the opioid crisis. Understanding the receptor's function and the body's response to its activation is crucial for developing safer analgesics and treatments for opioid addiction. Genetic variations in the OPRM1 gene have been linked to variations in pain sensitivity and the risk of developing opioid addiction.

Research Directions[edit | edit source]

Current research on the μ-opioid receptor focuses on developing drugs that can selectively target this receptor without the adverse effects associated with opioid use, such as respiratory depression and addiction. Another area of interest is the investigation of the receptor's structure to design more effective and safer analgesics.


WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD